Loading data for RLAY — first visit, this takes a few seconds.

Alert

Relay Therapeutics Inc. (RLAY)

NasdaqGM: RLAY · Real-Time Price · USD

18.77

-0.65 (-3.35%)

At close: Aug 28, 2026, 3:59 PM

19.10

+1.76%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

-3.35% (1D)

Bid	14.35
Market Cap	4.11B
Revenue (ttm)	10.35M
Net Income (ttm)	-286.04M
	1.70
	-1.56
	n/a
	-11.42
P/B (ttm)	4.61
P/S (ttm)	397.42
Earnings Date	Nov 5, 2026

Ask	24.83
Volume	2,762,698
Avg. Volume (20D)	3,325,120
Open	19.15
Previous Close	19.42
Day's Range	18.63 - 19.30
52-Week Range	3.57 - 21.27
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 16, 2020

Employees 202

Stock Exchange NasdaqGM

Ticker Symbol RLAY

Website https://www.relaytx.com

Full Company Profile

Financial Performance

In 2025, Relay Therapeutics's revenue was 15.36M, an increase of 53.44% compared to the previous year's 10.01M. Earnings were -276.48M, a decrease of -18.13%.

Financial Statements

Earnings Surprise

Relay Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $350K misses estimates by $0, with -48.30% YoY decline.
EPS of -0.41 misses estimates by -0.02, with 0.00% YoY growth.

Next Earnings Release

Relay Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 week ago · Investor's Business Daily

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.

1 week ago · Simply Wall St.

Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?

Relay Therapeutics (RLAY) reported second quarter 2026 results, with revenue of US$0.35 million and a net loss of US$83.71 million. This provides investors with fresh data on this clinical stage biote...

1 week ago · Zacks

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

1 week ago · Zacks

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

2 weeks ago · Barchart

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near...

Page 1 of 2

Relay Therapeutics Inc. (RLAY)